Replimune Group, Inc.
NASDAQ:REPLBiotechnology
Healthcare
$19.81 +1.85%
+$0.19 today
- Market cap
- $1.88B
- Beta
- 0.91
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$3.42
52W Low $1.50High $13.24
Volume 2.13M
Average 7.51M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$192.25M
FY 2025 · Annual
Investing Cash Flow
-$23.80M
FY 2025 · Annual
Financing Cash Flow
$252.40M
FY 2025 · Annual
+1450.1% YoYCash Flow Statement
USD
Metric | FY2021 Mar 2021 | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 |
|---|---|---|---|---|---|
| Net Income | (80.87M) | (118.04M) | (174.28M) | (215.79M) | (247.3M) |
| Depreciation & Amortization | 1.71M | 2.15M | 2.45M | 2.66M | 3.5M |
| Deferred Income Tax | 0 | 0 | 38K | 0 | 0 |
| Stock-Based Compensation | 11.79M | 24.25M | 28.13M | 34.13M | 35.04M |
| Change in Working Capital | 3.51M | 7.24M | 15.12M | 5.48M | 24.08M |
| Accounts Receivables | 325K | (247K) | (61K) | (1.92M) | 1.3M |
| Inventory | 0 | 247K | 61K | 0 | 0 |
| Accounts Payables | (1.03M) | 1.12M | 1.98M | (2.79M) | 9.94M |
| Other Working Capital | 4.22M | 6.12M | 13.14M | 10.19M | 12.84M |
| Other Non-Cash Items | 2.47M | 2.22M | 494K | (11.94M) | (7.58M) |
| Operating Cash Flow | (61.39M) | (82.18M) | (128.05M) | (185.47M) | (192.25M) |
| Capital Expenditures | (2.39M) | (2.34M) | (2.27M) | (5.66M) | (6.69M) |
| Acquisitions (Net) | 0 | (530) | 140.23K | 0 | 0 |
| Purchases of Investments | (392.43M) | (255.72M) | (583.41M) | (489.52M) | (403.59M) |
| Sales of Investments | 206.05M | 256.25M | 443.18M | 592.38M | 386.48M |
| Other Investing Activities | 0 | 530 | (140.23K) | 0 | 0 |
| Investing Cash Flow | (188.78M) | (1.81M) | (142.5M) | 97.2M | (23.8M) |
| Debt Repayment | (10.15M) | (264K) | 27.79M | 14.52M | (599K) |
| Common Stock Issued | 286.11M | 6.86M | 187.29M | 1.76M | 155.73M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 96.5M | 0 | 96.22M | 0 | 97.27M |
| Financing Cash Flow | 372.46M | 6.6M | 311.3M | 16.28M | 252.4M |
| Effect of Forex Changes | 721K | 818K | (109K) | (86K) | 315K |
| Net Change in Cash | 123.02M | (76.57M) | 40.64M | (72.07M) | 36.67M |
| Free Cash Flow | (63.78M) | (84.52M) | (130.32M) | (191.13M) | (198.94M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$247.3M
+ D&A$3.5M
+ Stock-Based Comp$35.0M
+ Deferred Tax$0
+ Working Capital$24.1M
- Other Non-Cash-$7.6M
= Operating Cash Flow-$192.3M
- Capex-$6.7M
= Free Cash Flow-$198.9M
Analysis
FY2025 free cash flow is -$198.9M. FCF conversion is 80.4% of net income. Operating cash flow was -$192.3M, with capex of -$6.7M. The largest bridge item is Stock-Based Comp at $35.0M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 10, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 9, 2026 | |
| 10-Q/A | 10-Q/A filing | Nov 6, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 3, 2026 |
Does REPL generate free cash flow?
Replimune Group, Inc. (REPL) generated -$198.94M of free cash flow in fiscal 2025.
How much operating cash flow does REPL produce?
Operating cash flow was -$192.25M, before capital expenditures of $6.69M.
Continue the stock analysis
Jump to another research area for this company.